6,963 publications from this institution
Objectives This study sought to study the efficacy and safety of newer-generation drug-eluting stents (DES) compared with bare-metal stents (BMS) in an appropriately powered population of patients with ST-segment elevation myocardial infarction (STEMI). Background Among patients with STEMI, early generation DES improved efficacy but not safety compared with BMS. Newer-generation DES, everolimus-eluting stents, and biolimus A9-eluting stents, have been shown to improve clinical outcomes compared with early generation DES. Methods Individual patient data for 2,665 STEMI patients enrolled in 2 large-scale randomized clinical trials comparing newer-generation DES with BMS were pooled: 1,326 patients received a newer-generation DES (everolimus-eluting stent or biolimus A9-eluting stent), whereas the remaining 1,329 patients received a BMS. Random-effects models were used to assess differences between the 2 groups for the device-oriented composite endpoint of cardiac death, target-vessel reinfarction, and target-lesion revascularization and the patient-oriented composite endpoint of all-cause death, any infarction, and any revascularization at 1 year. Results Newer-generation DES substantially reduce the risk of the device-oriented composite endpoint compared with BMS at 1 year (relative risk [RR]: 0.58; 95% confidence interval [CI]: 0.43 to 0.79; p = 0.0004). Similarly, the risk of the patient-oriented composite endpoint was lower with newer-generation DES than BMS (RR: 0.78; 95% CI: 0.63 to 0.96; p = 0.02). Differences in favor of newer-generation DES were driven by both a lower risk of repeat revascularization of the target lesion (RR: 0.33; 95% CI: 0.20 to 0.52; p < 0.0001) and a lower risk of target-vessel infarction (RR: 0.36; 95% CI: 0.14 to 0.92; p = 0.03). Newer-generation DES also reduced the risk of definite stent thrombosis (RR: 0.35; 95% CI: 0.16 to 0.75; p = 0.006) compared with BMS. Conclusions Among patients with STEMI, newer-generation DES improve safety and efficacy compared with BMS throughout 1 year. It remains to be determined whether the differences in favor of newer-generation DES are sustained during long-term follow-up.
Conference Article| May 01 1996 LIGAND-INDUCED DIFFERENTIATION OF GLUCOCORTICOID RECEPTOR (GR) TRANS-REPRESSION AND TRANSACTIVATION Ian M. Adcock; Ian M. Adcock 1Thoracic Medicine, National Heart & Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK Search for other works by this author on: This Site PubMed Google Scholar Peter J. Barnes Peter J. Barnes 1Thoracic Medicine, National Heart & Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK Search for other works by this author on: This Site PubMed Google Scholar Biochem Soc Trans (1996) 24 (2): 267S. https://doi.org/10.1042/bst024267s Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation Ian M. Adcock, Peter J. Barnes; LIGAND-INDUCED DIFFERENTIATION OF GLUCOCORTICOID RECEPTOR (GR) TRANS-REPRESSION AND TRANSACTIVATION. Biochem Soc Trans 1 May 1996; 24 (2): 267S. doi: https://doi.org/10.1042/bst024267s Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBiochemical Society Transactions Search Advanced Search This content is only available as a PDF. © 1996 Biochemical Society1996 Article PDF first page preview Close Modal You do not currently have access to this content.
Plasma catecholamines in exercise-induced asthma Sir,-The results
Acute complications and restenosis in the first few months after a successful procedure remain the two major limitations of coronary balloon angioplasty. New devices have been developed in order to avoid these limitations. We tested the directional atherectomy catheter clinically and compared the immediate quantitatively analysed results with two other recently developed devices and conventional balloon angioplasty. A gain in luminal diameter of 1.7 mm after atherectomy was observed in 7 patients. This is far more than could be accomplished by balloon angioplasty, stenting and rotablation. Furthermore, the size of the device in relation to the size of the obstructed vessel suggests that a Dotter effect is partly responsible for the gain in luminal diameter. Whether this large gain can prevent restenosis remains to be confirmed. Preliminary literature data suggest that this is not the case.
Cette etude montre que des etudes complementaires sont necessaires pour demontrer son role dans la regulation du tonus bronchique dans l'asthme